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background:  While animal studies have documented cardio-protective effects of metformin, the impact in humans remains elusive. 
We investigated the effect of metformin on myocardial infarct size in diabetic patients presenting with ST-segment elevation myocardial 
infarction (STEMI).
methods:  Data extraction utilized the National Cardiovascular Data CathPCI Registry in all known diabetics of age 18 years or older, 
presenting with STEMI or STEMI equivalent at two academic medical centers from January 2010 to December 2013. The exposure of 
interest was ongoing metformin use prior to the event. Prior to matching, two-sample t-test, chi-square or Fisher’s exact test and d-score 
showed that the two groups (metformin, non-metformin) were not comparable on several key prognostic variables. In order to achieve 
comparability, propensity-score matching was utilized for 15 potential individual and combined predictor variables with acceptable d-scores 
of <10% for all matched pairs, confirming an efficient matching procedure. Primary study outcome was myocardial infarct size, reflected by 
peak serum creatine kinase-myocardial band (CKMB), troponin-T and hospital discharge left ventricular ejection fraction (DCLVEF).
Results:  Of all 1,726 STEMI cases reviewed, 493 subjects had diabetes (28.5 %), with 208 metformin users and 285 non-users. Matched 
pairs analysis yielded 137 cases per group. The arithmetic difference of total peak serum CKMB and troponin-T between metformin and 
non-metformin groups were -18.1 ng/ml ((95% confidence interval (CI) -55.0 to 18.8; p= 0.56)) and -1.1 ng/ml (95% CI -2.8 to 0.5; p=0.41) 
respectively. Similarly, the relative percent difference of CKMB and troponin-T between groups were -6.5% (95% CI -28.7 % to 22.5 %; 
p=0.62) and 5.7% (95 % CI -19% to 38.1%; p=0.68). Median DCLVEF in both groups was 45. Arithmetic difference of DCLVEF between 
metformin and non-metformin users was 0.7 % (95% CI -2.2 to 3.6; p=0.98). For all measured outcome variables, there were no statistically 
significant differences between the groups.
conclusion:  The proposed cardio-protective effect of metformin does not appear to influence myocardial infarct size in diabetic patients 
with acute STEMI.
